RU2015151626A3 - - Google Patents

Download PDF

Info

Publication number
RU2015151626A3
RU2015151626A3 RU2015151626A RU2015151626A RU2015151626A3 RU 2015151626 A3 RU2015151626 A3 RU 2015151626A3 RU 2015151626 A RU2015151626 A RU 2015151626A RU 2015151626 A RU2015151626 A RU 2015151626A RU 2015151626 A3 RU2015151626 A3 RU 2015151626A3
Authority
RU
Russia
Application number
RU2015151626A
Other languages
Russian (ru)
Other versions
RU2731717C2 (ru
RU2015151626A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201308017A external-priority patent/GB201308017D0/en
Priority claimed from GB201320339A external-priority patent/GB201320339D0/en
Application filed filed Critical
Publication of RU2015151626A publication Critical patent/RU2015151626A/ru
Publication of RU2015151626A3 publication Critical patent/RU2015151626A3/ru
Application granted granted Critical
Publication of RU2731717C2 publication Critical patent/RU2731717C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
RU2015151626A 2013-05-03 2014-04-29 Способ экспрессии RU2731717C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1308017.1 2013-05-03
GB201308017A GB201308017D0 (en) 2013-05-03 2013-05-03 Expression process
GB1320339.3 2013-11-18
GB201320339A GB201320339D0 (en) 2013-11-18 2013-11-18 Expression Process
PCT/GB2014/000165 WO2014177826A1 (en) 2013-05-03 2014-04-29 Expression process

Publications (3)

Publication Number Publication Date
RU2015151626A RU2015151626A (ru) 2017-06-08
RU2015151626A3 true RU2015151626A3 (https=) 2018-03-20
RU2731717C2 RU2731717C2 (ru) 2020-09-08

Family

ID=50639794

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015151626A RU2731717C2 (ru) 2013-05-03 2014-04-29 Способ экспрессии

Country Status (12)

Country Link
US (3) US9873891B2 (https=)
EP (1) EP2992104B1 (https=)
JP (1) JP6545153B2 (https=)
KR (1) KR102180660B1 (https=)
CN (2) CN114395584B (https=)
BR (1) BR112015027373A2 (https=)
CA (1) CA2910877C (https=)
DK (1) DK2992104T3 (https=)
ES (1) ES2732907T3 (https=)
RU (1) RU2731717C2 (https=)
SG (1) SG11201508447TA (https=)
WO (1) WO2014177826A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
CN111465686B (zh) 2017-12-11 2024-03-22 富士胶片株式会社 动物细胞、动物细胞的制造方法及靶蛋白的制造方法
WO2020122049A1 (ja) 2018-12-11 2020-06-18 富士フイルム株式会社 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法
CN109837277A (zh) * 2019-03-01 2019-06-04 深圳生生凡非基因技术有限公司 一种cpgk嵌合型启动子、腺相关病毒载体及其应用
WO2021107123A1 (ja) 2019-11-29 2021-06-03 富士フイルム株式会社 細胞培養方法、抗体製造方法、有機酸除去方法、及び、抗体
WO2022149607A1 (ja) 2021-01-07 2022-07-14 富士フイルム株式会社 細胞の選択方法、装置、及び装置システム
WO2022196710A1 (ja) 2021-03-17 2022-09-22 富士フイルム株式会社 細胞培養方法、及び有用物質の製造方法
CN112980852B (zh) * 2021-05-18 2021-08-13 北京华芢生物技术有限公司 新型冠状病毒b.1.351南非突变株rbd的基因及其应用
US20230011134A1 (en) 2021-05-27 2023-01-12 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
EP4410957A4 (en) 2021-09-30 2026-01-28 Fujifilm Corp CELL CULTURE PROCESS AND PROCESS FOR PRODUCING USEFUL SUBSTANCE
EP4450609A1 (en) 2021-12-15 2024-10-23 FUJIFILM Corporation Method for producing product, and cell culture apparatus
CN118974267A (zh) 2022-03-28 2024-11-15 富士胶片株式会社 产物的生产方法及产物
JPWO2023190829A1 (https=) 2022-03-31 2023-10-05
JPWO2023238949A1 (https=) 2022-06-10 2023-12-14
EP4596704A4 (en) 2022-09-29 2026-03-11 Fujifilm Corp PRODUCT PRODUCTION PROCESS
WO2024248118A1 (ja) 2023-05-31 2024-12-05 富士フイルム株式会社 細胞培養方法および生産物の製造方法
CN121175432A (zh) 2023-05-31 2025-12-19 富士胶片株式会社 生产物的生产方法
EP4722377A1 (en) 2023-05-31 2026-04-08 FUJIFILM Corporation Method for producing product
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003223766A1 (en) * 2002-04-30 2003-11-17 University Of North Carolina At Chapel Hill Secretion signal vectors
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
MX2009007139A (es) * 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
KR101618767B1 (ko) * 2008-09-02 2016-05-09 한국생명공학연구원 외래단백질을 고효율로 생산하는 리더서열
CA2746350C (en) * 2008-12-31 2018-06-12 Bharat Serums And Vaccines Ltd. Anti-rhd monoclonal antibodies
TWI541021B (zh) 2009-03-05 2016-07-11 艾伯維有限公司 Il-17結合蛋白
GB0905331D0 (en) * 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
KR101420274B1 (ko) * 2011-06-13 2014-07-21 주식회사 종근당 Csp-b 5'sar 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법

Also Published As

Publication number Publication date
US20180127777A1 (en) 2018-05-10
CA2910877A1 (en) 2014-11-06
US20220213500A1 (en) 2022-07-07
DK2992104T3 (da) 2019-07-15
CA2910877C (en) 2021-08-03
CN114395584B (zh) 2025-01-28
EP2992104A1 (en) 2016-03-09
JP6545153B2 (ja) 2019-07-17
SG11201508447TA (en) 2015-11-27
CN114395584A (zh) 2022-04-26
EP2992104B1 (en) 2019-04-17
KR20160003705A (ko) 2016-01-11
BR112015027373A2 (pt) 2017-08-29
US11306323B2 (en) 2022-04-19
JP2016517691A (ja) 2016-06-20
US9873891B2 (en) 2018-01-23
RU2731717C2 (ru) 2020-09-08
WO2014177826A1 (en) 2014-11-06
ES2732907T3 (es) 2019-11-26
US20160076051A1 (en) 2016-03-17
KR102180660B1 (ko) 2020-11-19
CN105392889A (zh) 2016-03-09
RU2015151626A (ru) 2017-06-08

Similar Documents

Publication Publication Date Title
AP2016009275A0 (https=)
BR112015007533A2 (https=)
BR102016010778A2 (https=)
BR112016009018A2 (https=)
BR112014017733A2 (https=)
BR112014017739A2 (https=)
BR112014019326A2 (https=)
BR112014017855A2 (https=)
BR112015016561A2 (https=)
BR112014020341A2 (https=)
BR112014017765A2 (https=)
BR112014017669A2 (https=)
BR112014021878A2 (https=)
BR112016004862A2 (https=)
BR112016001142A2 (https=)
RU2015151626A3 (https=)
BR112014017901A2 (https=)
BR112014018207A2 (https=)
BR112015015948A2 (https=)
BR112016007782A2 (https=)
BR112014017722A2 (https=)
BR112014017794A2 (https=)
BR112014017653A2 (https=)
BR112014017601A2 (https=)
BR112014017745A2 (https=)